Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Access Pharmaceuticals has announced that MuGard, its oral mucositis product, has been launched in Germany, Italy, UK, Greece and the Nordic countries by its European commercial partner, SpePharm. MuGard is ready to use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of many anticancer treatments.
Subscribe to our email newsletter
MuGard forms a protective coating over the oral mucosa when swirled gently around the mouth.
In a comparison of cancer patients receiving standard mucositis care with those patients receiving MuGard, the incidence and severity of mucositis was significantly lower in the MuGard treated group using a validated scale for the assessment of oral mucositis, said the company.
Access Pharmaceuticals focuses on the areas of oncology and supportive care of cancer patients. The company has recently acquired product candidates in the dermatology field as well as additional oncology assets. Access has an approved supportive care product, one product in Phase 3 clinical development, four Phase 2 clinical candidates, and six preclinical programs in oncology, including products arising from a promising oral drug delivery technology.